These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 29260740)

  • 21. Unmet Needs in Clinical and Basic Hepatitis B Virus Research.
    Su TH; Kao JH
    J Infect Dis; 2017 Nov; 216(suppl_8):S750-S756. PubMed ID: 29156048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA.
    Kumar R; Pérez-Del-Pulgar S; Testoni B; Lebossé F; Zoulim F
    Liver Int; 2016 Jan; 36 Suppl 1():72-7. PubMed ID: 26725901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection.
    Meng Z; Chen Y; Lu M
    Front Immunol; 2019; 10():3127. PubMed ID: 32117201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus.
    Ely A; Arbuthnot P
    Discov Med; 2015 Sep; 20(109):137-43. PubMed ID: 26463095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.
    Durantel D; Zoulim F
    J Hepatol; 2016 Apr; 64(1 Suppl):S117-S131. PubMed ID: 27084032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Getting to HBV cure: The promising paths forward.
    Fung S; Choi HSJ; Gehring A; Janssen HLA
    Hepatology; 2022 Jul; 76(1):233-250. PubMed ID: 34990029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Control of viral transcripts as a concept for future HBV therapies.
    Seeger C
    Curr Opin Virol; 2018 Jun; 30():18-23. PubMed ID: 29453098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus.
    Ely A; Moyo B; Arbuthnot P
    Mol Ther; 2016 Apr; 24(4):671-7. PubMed ID: 26916283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).
    Revill P; Locarnini S
    Curr Opin Pharmacol; 2016 Oct; 30():144-150. PubMed ID: 27639371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic hepatitis B: New potential therapeutic drugs target.
    Leowattana W; Leowattana T
    World J Virol; 2022 Jan; 11(1):57-72. PubMed ID: 35117971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.
    Yang HC; Kao JH
    Emerg Microbes Infect; 2014 Sep; 3(9):e64. PubMed ID: 26038757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9.
    Li H; Sheng C; Wang S; Yang L; Liang Y; Huang Y; Liu H; Li P; Yang C; Yang X; Jia L; Xie J; Wang L; Hao R; Du X; Xu D; Zhou J; Li M; Sun Y; Tong Y; Li Q; Qiu S; Song H
    Front Cell Infect Microbiol; 2017; 7():91. PubMed ID: 28382278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel developments of hepatitis B: treatment goals, agents and monitoring tools.
    Mak LY; Seto WK; Fung J; Yuen MF
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):109-120. PubMed ID: 30621472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in therapeutics for chronic hepatitis B.
    Yang N; Bertoletti A
    Hepatol Int; 2016 Mar; 10(2):277-85. PubMed ID: 26363922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drugs in Development for Hepatitis B.
    Dawood A; Abdul Basit S; Jayaraj M; Gish RG
    Drugs; 2017 Aug; 77(12):1263-1280. PubMed ID: 28660478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic Hepatitis B Infection: New Approaches towards Cure.
    Ogunnaike M; Das S; Raut SS; Sultana A; Nayan MU; Ganesan M; Edagwa BJ; Osna NA; Poluektova LY
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of CRISPR/Cas9 Technology to HBV.
    Lin G; Zhang K; Li J
    Int J Mol Sci; 2015 Nov; 16(11):26077-86. PubMed ID: 26540039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA Polymerase κ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus.
    Qi Y; Gao Z; Xu G; Peng B; Liu C; Yan H; Yao Q; Sun G; Liu Y; Tang D; Song Z; He W; Sun Y; Guo JT; Li W
    PLoS Pathog; 2016 Oct; 12(10):e1005893. PubMed ID: 27783675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel therapeutic strategies for chronic hepatitis B.
    Phillips S; Jagatia R; Chokshi S
    Virulence; 2022 Dec; 13(1):1111-1132. PubMed ID: 35763282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.